Pharmaceutical News

RSS

Intravenous ibuprofen: A key addition to perioperative pain management

Hendersonville Medical Center today announced that anesthesiologist Peter B. Kroll, M.D., has published an article in the January issue of peer-reviewed medical journal Pain Management.

23 Feb 2012

Scientists design compounds that act against myotonic dystrophy type 1 RNA

While RNA is an appealing drug target, small molecules that can actually affect its function have rarely been found. But now scientists from the Florida campus of The Scripps Research Institute have for the first time designed a series of small molecules that act against an RNA defect directly responsible for the most common form of adult-onset muscular dystrophy.

23 Feb 2012

Burma unable to expand HIV, TB treatment programs without more donor support, MSF report says

Approximately 85,000 HIV-positive people in Burma, also known as Myanmar, are in need of antiretroviral treatment (ART) and cannot access it "due to a lack of funding, despite renewed international engagement with the government amid a wave of political reform, according to a report released Wednesday" by the medical aid group Medecins Sans Frontieres (MSF), the Associated Press/CBS News reports.

23 Feb 2012

Actelion, Auxilium partner to develop and commercialize XIAFLEX

Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. announced today that they have entered into a long-term partnership for the development, supply and commercialization of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the potential treatment of Dupuytren's contracture and Peyronie's disease.

23 Feb 2012

FDA approves Boston Scientific's ION and TAXUS Liberte paclitaxel-eluting stents

Boston Scientific Corporation's ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System and TAXUS Liberte Paclitaxel-Eluting Coronary Stent System have received U.S. Food and Drug Administration (FDA) approval for use in patients experiencing an acute myocardial infarction (AMI), or heart attack.

23 Feb 2012

Novartis delivers 100 million child-friendly antimalarial treatments to 39 countries

One hundred million treatments of Coartem- Dispersible (artemether-lumefantrine), an antimalarial developed especially for children with Plasmodium falciparum malaria, have been delivered by Novartis to 39 malaria-endemic countries, Medicines for Malaria Venture (MMV) announced today.

23 Feb 2012

FDA EMDAC recommends approval of VIVUS' Qnexa for obesity

VIVUS, Inc. today announced that the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended Qnexa be granted marketing approval by the FDA for the treatment of obesity in adults.

23 Feb 2012

Health Canada accepts Paladin's Silenor NDS for review

Paladin Labs Inc. and Somaxon Pharmaceuticals, Inc. today announced that Paladin has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for Silenor (doxepin) for the treatment and symptomatic relief of insomnia.

23 Feb 2012

Depomed, Santarus reach agreement to resolve GLUMETZA patent litigation with Lupin

Santarus, Inc. and Depomed, Inc. today announced that they have entered into a settlement agreement with Lupin Ltd. and its subsidiary, Lupin Pharmaceuticals, Inc., to resolve pending patent litigation involving GLUMETZA 1000 mg and 500 mg.

23 Feb 2012

Statins can reduce risk of depression

Researchers at Charité - Universitätsmedizin Berlin and the University of California San Francisco have studied the link between medication taken for cardiovascular disease and the development of depression. In their studies, scientists have determined that a particular class of medication, i.e. statins, can reduce the risk of developing depression.

22 Feb 2012

Making a medicinewise choice between brands

Following reports the first generic version of atorvastatin will be hitting pharmacy shelves this week, NPS is urging consumers to be medicinewise when making a choice between medicine brands.

22 Feb 2012

FDA approves new supplies of drugs that are facing shortages

The United States Food and Drugs Administration (FDA) have approved new suppliers for two crucial cancer drugs, easing critical shortages that had been concerning patients and families particularly of the children with leukemia. But there are currently 283 separate prescription drugs in short supply or unavailable nationwide, and regulators and manufacturers say shortages are a long-term problem that will continue to scare patients and doctors.

22 Feb 2012

Counterfeit drugs on the Internet find their way into legitimate pharmacies

Criminal gangs are increasingly using the internet to market life-threatening counterfeit medicines and some have even turned up in legitimate outlets such as pharmacies, according to a review led by Dr Graham Jackson, editor of IJCP, the International Journal of Clinical Practice, and published in the March edition.

22 Feb 2012

Study aims to achieve early detection of heart disease

With the month of February designated as Heart Health Month, physician-researchers in the Division of Cardiology at the Los Angeles Biomedical Research Institute (LA BioMed) - Dr. Matthew Budoff and Dr. Ronald Oudiz - continue to pave the way with their efforts to develop treatments and therapies for conditions affecting the heart, and to help improve overall heart health.

22 Feb 2012

UMMS' iHeal project uses emerging technologies to detect drug cravings and intervene

Clinical researchers at the University of Massachusetts Medical School (UMMS) are combining an innovative constellation of technologies such as artificial intelligence, smartphone programming, biosensors and wireless connectivity to develop a device designed to detect physiological stressors associated with drug cravings and respond with user-tailored behavioral interventions that prevent substance use.

22 Feb 2012

FDA approves APP's preservative-free Methotrexate Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market preservative-free Methotrexate Injection, USP. APP currently manufactures Methotrexate Injection with preservative.

22 Feb 2012

Russian government's censorship of websites with harm reduction methods for drug users helps fuel HIV epidemic, IPS reports

"A recent government crackdown on Russian media, particularly online information portals specializing in health tips and harm reduction methods for drug users, has sparked widespread public opposition, with critics claiming that the 'draconian silencing' of public health advocates could worsen an already perilous health situation in the country," Inter Press Service reports.

22 Feb 2012

BioLineRx BL-7010 may reduce gluten toxicity in patients with celiac disease

BioLineRx, a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient's body).

22 Feb 2012

New chemical compound to treat brain damage from stroke

Researchers at the University of Copenhagen have designed, produced and patented a new chemical compound for the possible treatment of brain damage caused by stroke. The compound binds 1,000 times more effectively to the target protein in the brain than the potential drug currently being tested on stroke victims.

22 Feb 2012

Promising antibiotic alternative to fight bacteria that causes strep throat

Researchers have discovered a promising alternative to common antibiotics used to fight the bacteria that causes strep throat. In an article published in the Proceedings of the National Academy of Sciences, the scientists discussed how their discovery could fight the infection with a reduced risk of antibiotic resistance.

22 Feb 2012